Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alogliptin Safety and Efficacy in Indian Patients with T2DM
NCT03042325Phase 4Withdrawn
- Sponsor
- Takeda
- Start
- Jul 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of alogliptin in type 2 diabetes mellitus (T2DM), sponsored by Takeda. Primary endpoints: Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) at 30 weeks, Percentage of Participants with Adverse Drug Reactions (ADRs) and Unexpected ADRs at 30 weeks and 2 more. Planned start Jul 2017; status: withdrawn.
02
Drugs
alogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03042325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042325.